Core Viewpoint - The CSI Hong Kong Stock Connect Biotechnology Theme Index has shown significant growth, with a 5.26% increase over the past month, 20.82% over the past three months, and 25.29% year-to-date, reflecting strong performance in the biotechnology sector [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Biotechnology Theme Index is currently at 1183.16 points, having been established with a base date of December 28, 2018, at 1000.0 points [1]. - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, selected from the Hong Kong Stock Connect range [1]. Group 2: Index Holdings - The top ten weighted companies in the index include: BeiGene (14.31%), WuXi Biologics (12.72%), Innovent Biologics (10.78%), CanSino Biologics (7.78%), CSPC Pharmaceutical Group (6.03%), China Biologic Products (5.8%), Hansoh Pharmaceutical (3.57%), Kelun-Biotech (3.31%), Zai Lab (3.29%), and WuXi AppTec (3.23%) [1]. - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1]. Group 3: Industry Composition - The industry composition of the index holdings is as follows: biopharmaceuticals account for 50.37%, chemical drugs for 25.76%, pharmaceutical and biotechnology services for 20.60%, and medical devices for 3.27% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December, with a sample adjustment limit of 20% [2].

Group 1 - The core index of the CSI Hong Kong Stock Connect Biotechnology Theme Index closed at 1134.61 points, with a decline of 3.59% over the past month, an increase of 24.05% over the past three months, and a year-to-date increase of 20.15% [1] - The index consists of 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of biotechnology theme companies within the Hong Kong Stock Connect [1] - The index was established on December 28, 2018, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: BeiGene (15.69%), WuXi Biologics (11.81%), Innovent Biologics (10.68%), CanSino Biologics (8.36%), CSPC Pharmaceutical Group (6.36%), China Biologic Products (5.81%), Hansoh Pharmaceutical (3.68%), Zai Lab (3.48%), 3SBio (3.22%), and WuXi AppTec (2.82%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 52.00%, chemical drugs for 25.67%, pharmaceutical and biotechnology services for 19.19%, and medical devices for 3.14% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, with a sample adjustment ratio generally not exceeding 20% [2] - Special adjustments may occur under certain circumstances, such as delisting or significant corporate actions like mergers or acquisitions [2]